Percheron Therapeutics Limited Corporate Presentation

Aug 31, 2026 at 9:01 PM EDT · Issued by Percheron Therapeutics Limited via ASX

Filed with ASX · Aug 31, 2026 at 9:01 PM EDT

On 6ix: 6ix.com/news/percheron-therapeutics-limited-corporate-presentation

Percheron Therapeutics Limited ABN 41 095 060 745 ASX: PER | FSE: AWY | US OTC: ATHJY PERCHERON THERAPEUTICS CORPORATE PRESENTATION Melbourne, Australia – 1 September 2026: Percheron Therapeutics Limited (ASX: PER) (‘the Company’), an international biotechnology...

View Attachment

6ix hasn’t read this filing yet.

Percheron Therapeutics Limited on 6ix

In the deck

Percheron Therapeutics — Investor Presentation (September 2026)14 slidesSep 1, 2026

Earlier from Percheron Therapeutics

Percheron raises $2.3m to fully fund clinical trial in AMLAug 31
Proposed issue of securities - PERAug 31
Initial Director's Interest NoticeAug 31
Transitional appointment of Executive DirectorAug 31
Change of Director's Interest NoticeAug 31

Later from Percheron Therapeutics

2026 Notice of Annual General MeetingSep 6
Application for quotation of securities - PERSep 6
Notice under S708ASep 7
Dr Michael Baker Commences as CEO and MDOct 4
Final Director's Interest NoticeOct 4

All Percheron Therapeutics news releases

Follow Percheron Therapeutics into a list and get an email when it puts out news.

Follow Percheron Therapeutics